Novel lipoproteoplex delivers Keap1 siRNA based gene therapy to accelerate diabetic wound healing

Publication date: July 2017
Source:Biomaterials, Volume 132
Author(s): Piul S. Rabbani, Anna Zhou, Zachary M. Borab, Joseph A. Frezzo, Nikita Srivastava, Haresh T. More, William J. Rifkin, Joshua A. David, Samuel J. Berens, Raymond Chen, Sophia Hameedi, Muhammad H. Junejo, Camille Kim, Rita A. Sartor, Che F. Liu, Pierre B. Saadeh, Jin K. Montclare, Daniel J. Ceradini
Therapeutics utilizing siRNA are currently limited by the availability of safe and effective delivery systems. Cutaneous diseases, specifically ones with significant genetic components are ideal candidates for topical siRNA based therapy but the anatomical structure of skin presents a considerable hurdle. Here, we optimized a novel liposome and protein hybrid nanoparticle delivery system for the topical treatment of diabetic wounds with severe oxidative stress. We utilized a cationic lipid nanoparticle (CLN) composed of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and the edge activator sodium cholate (NaChol), in a 6:1 ratio of DOTAP:NaChol (DNC). Addition of a cationic engineered supercharged coiled-coil protein (CSP) in a 10:1:1 ratio of DNC:CSP:siRNA produced a stable lipoproteoplex (LPP) nanoparticle, with optimal siRNA complexation, minimal cytotoxicity, and increased transfection efficacy. In a humanized murine diabetic wound healing model, our optimized LPP formulation successfully delivered siRNA targeted against Keap1, key repressor of Nrf2 which is a central regulator of redox mechanisms. Application of LPP complexing siKeap1 restored Nrf2 antioxidant function, accelerated diabetic tissue regeneration, and augmented reduction-oxidation homeostasis in the wound environment. Our topical LPP delivery system can readily be translated into clinical use for the treatment of diabetic wounds and can be extended to other cutaneous diseases with genetic components.

Graphical abstract

http://ift.tt/2oFUkjg